|
Zimbabwe Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Zimbabwe Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Zimbabwe.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Zimbabwean pharmaceutical and healthcare industry.
Competitive intelligence, Zimbabwean pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Zimbabwean market.
The Zimbabwe Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Zimbabwe Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Zimbabwean pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Zimbabwe to test other views – a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Zimbabwean Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Zimbabwe.
- Exploit The Latest Competitive Zimbabwean Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Zimbabwe.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Zimbabwe Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Zimbabwe Pharmaceuticals And Healthcare Industry SWOT |
| Zimbabwe Political SWOT |
| Zimbabwe Economic SWOT |
| Zimbabwe Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Pricing And Reimbursement Issues |
| Public Drug Procurement |
Chapter - Industry Developments |
| Epidemiology |
| HIV/AIDS Situation |
| Healthcare System |
| Healthcare Funding |
| Healthcare Staff |
| Pharmaceutical Sector |
| Recent Pharmaceutical Sector Developments |
| Table: ARV Prices Available Through Direct Purchase From Roche (CHF) |
| Traditional Medicine |
| Biotechnology Sector Developments |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecasts |
| Table: Drug Market Forecast, 2004-2013 |
| Key Growth Factors – Industry |
| Key Growth Factors – Industry |
| Table: Healthcare Expenditure Forecast, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Key Growth Factors – Macroeconomic |
| Zimbabwe - Economic Activity |
| Prescription Drug Market Forecast |
| Table: Prescription Drug Market Indicators, 2004-2013 (ZWDmn unless otherwise indicated) |
| OTC Drug Market Forecast |
| Table: OTC Drug Market Forecast, 2004-2013 (ZWDmn unless otherwise indicated) |
| Patented Drug Market Forecast |
| Table:Patented Market Forecast, 2004-2013 |
| Generic Drug Market Forecast |
| Table: Generic Drug Market Indicators*, 2004-2013 |
| Export/Import Forecasts |
| Table: Pharmaceutical Trade Balance, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Other Healthcare Data Forecasts |
| Table: Zimbabwe's Other Healthcare Forecasts, 2004-2013 |
| Key Risks To BMI Forecasts |
Chapter - Competitive Landscape |
| Company Profiles |
| Multinational Companies |
| Ranbaxy |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| GlaxoSmithKline |
| Indigenous Companies |
| Datlabs |
| Varichem Laboratories |
| CAPS Holdings |
Chapter - Country Snapshot: Zimbabwe Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000-2003 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 1997 And 1999* |
| Table: Average Annual Manufacturing Wages, 1996-2002 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Zimbabwe Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
We have forecast market values through to 2013, however we caution that future prospects are virtually impossible to assess properly. The task is made more difficult by the fact that – for several years now – official data-gathering has effectively ceased, which, coupled with hyperinflation, makes any sound and comprehensive analysis of the real economy extremely problematic. For this Q209 Pharmaceutical and Healthcare report, BMI has forecast that the prescription drug market – as a proportion of total pharmaceutical spending – will decrease from 85% in 2008 to 76% by 2013. Despite the widespread low-income capability of the population and rampant inflation, generic drugs will remain at a stagnant 5% of the total drug market during the forecast period. Growth is driven by international donations, high demand for over-the-counter (OTC) analgesics and the epidemiological profile of HIV, tuberculosis and malaria burdens on the healthcare sector.
Beginning in August 2008, the national disaster in Zimbabwe gave rise to a severe cholera outbreak in November 2008. Its transmission and escalation to epidemic levels has resulted from the progressively deteriorating health sector, with over 1,000 people believed to have died from cholera by December 2008. BMI believes that the situation is set to significantly worsen through to Q309.
In late November 2008 the health sector in Zimbabwe was in a critical state. Poor remuneration and retention depleted the number of qualified medical staff in the country, leaving those that stayed in hospitals with drug shortages and ineffective equipment. BMI believes that political indecisiveness coupled with continued corruption has prevented the distribution of funds, impacting heavily on the healthcare sector, with the latest cholera epidemic underlining the extent of the disaster.
To date (March 2009), the cholera crisis shows marginal signs of improvement. Having reached the embarrassing level of a humanitarian disaster, cases have spread into South Africa and Botswana through border towns. While international aid has alleviated scant resources, the spectacle of devastation has left thousands dead or incapacitated. Despite this, President Robert Mugabe has distracted himself with prolonged power-sharing talks with the opposition leader. While such a coalition may not reduce Mugabe’s influence over the population, it symbolises some form of political change. BMI notes that Zimbabwe’s misguided governance has contributed to the scale of this disaster, and has exposed the country as almost entirely reliant on international aid.
|
Zimbabwe Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria and South Africa |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |